読み込み中
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
前日終値
$12.08
+$0.15 · +1.26%
日中の時刻はETです。市場データは遅延する場合があります。
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
日中レンジ
現在 $12.08
52週レンジ
現在 $12.08
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
44
まちまち
リスク
68
高リスク
モメンタム
65
上昇基調
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
日中レンジ
現在 $12.08
52週レンジ
現在 $12.08
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 414万 USD | — | — | — | — |
| 粗利益 | −414万 USD | — | — | — | — |
| 研究開発 | 6.35億 USD | 7.96億 USD | 3.73億 USD | 4.37億 USD | 1.81億 USD |
| 販売・一般管理 | 1.06億 USD | 8924万 USD | 6277万 USD | 1.31億 USD | 3741.4万 USD |
| 営業費用 | 7.41億 USD | 8.85億 USD | 4.36億 USD | 5.68億 USD | 2.19億 USD |
| 受取利息 | 1458.5万 USD | 2133.4万 USD | 1772.5万 USD | — | — |
| 減価償却費と償却費 | 992.2万 USD | 785.5万 USD | 691.2万 USD | 138.6万 USD | 139.3万 USD |
| 営業利益 | −7.45億 USD | −8.85億 USD | −4.36億 USD | −5.68億 USD | −2.19億 USD |
| 純利益 | −7.39億 USD | −8.46億 USD | −4.08億 USD | −5.7億 USD | −2.14億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P Biotech ETFXBI4472.93万0.45%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM4190.91万0.05%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF2297.99万0.02%954億 USD0.05%$235+0.80%
iShares Russell 2000 Growth ETFIWO1470.27万0.11%139.17億 USD0.24%$356.78+0.94%
iShares Biotechnology ETFIBB1188.13万0.11%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO1171.46万0.06%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA784.13万0.04%218.24億 USD0.03%$32.79+0.40%
Simplify Health Care ETFPINK609.97万1.91%3.19億 USD0.51%$38.527+2.57%State Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHASimplify Health Care ETFPINKAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
